RECRUITINGOBSERVATIONAL
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
About This Trial
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Male and female recipients of all races, ≥18 years of age.
2. Patients undergoing primary or subsequent living or deceased donor liver transplantation.
3. Subject and/or guardian must be able to provide willing to sign a consent form.
4. Subject and/or guardian must be able to comply with the study protocol.
Who Should NOT Join This Trial:
1\. Inability or unwillingness of a participant and/or guardian to provide willing to sign a consent form.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Male and female recipients of all races, ≥18 years of age.
2. Patients undergoing primary or subsequent living or deceased donor liver transplantation.
3. Subject and/or guardian must be able to provide informed consent.
4. Subject and/or guardian must be able to comply with the study protocol.
Exclusion Criteria:
1\. Inability or unwillingness of a participant and/or guardian to provide informed consent.
Locations (1)
Northwestern Memorial Hospital
Chicago, Illinois, United States